<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814515</url>
  </required_header>
  <id_info>
    <org_study_id>NVG06C103</org_study_id>
    <nct_id>NCT00814515</nct_id>
  </id_info>
  <brief_title>Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007
      (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to
      Severe Dry Eye Syndrome
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal fluorescein staining (on modified Oxford scale)</measure>
    <time_frame>Approximately 26 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's global score of all symptoms of ocular discomfort unrelated to study medication instillation, using a visual analog scale (VAS) ranging from 0%-100%</measure>
    <time_frame>Approximately 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Ocular Symptom Disease Index© (OSDI©) questionnaire • Percentage of complete responder to corneal fluorescein staining (on modified Oxford scale), i.e. with corneal staining score =0 • Patient's score of each symptom of ocular discomfort unrelated to</measure>
    <time_frame>Approximately 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">482</enrollment>
  <condition>Moderate to Severe Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclosporin 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOVA22007 (Ciclosporin 0.1%)</intervention_name>
    <description>Ciclosporin 0.1% Ophthalmic Emulsions</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOVA22007</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 18 years of age or greater.

          -  At baseline, moderate to severe dry eye condition persisting despite conventional
             management.

        Exclusion Criteria:

          -  Presence or history of any systemic or ocular disorder or condition, including ocular
             surgery, trauma or disease that could possibly interfere with the interpretation of
             study results.

          -  Any relevant ocular anomaly interfering with the ocular surface, including post
             radiation keratitis, Stevens-Johnson syndrome, corneal ulcer history or concomitant
             corneal ulcer of infectious origin, etc.

          -  Any other ocular diseases requiring topical ocular treatment during the study period.

          -  Patient who has participated in a clinical trial with a new active substance during
             the past month before study entry.

          -  Participation in another clinical study at the same time as the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital des XV-XX</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <last_update_submitted>July 15, 2010</last_update_submitted>
  <last_update_submitted_qc>July 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mourad AMRANE, MD</name_title>
    <organization>Novagali Pharma</organization>
  </responsible_party>
  <keyword>Moderate</keyword>
  <keyword>Severe</keyword>
  <keyword>Dry</keyword>
  <keyword>Eye</keyword>
  <keyword>Ciclosporin</keyword>
  <keyword>Cyclosporine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

